This double-blinded placebo-controlled study will examine the incidence and significance of
contrast-induced acute kidney injury following IV iodine-based contrast material
administration in subjects with stage IIIB or stage IV chronic kidney disease.
Subjects will be scheduled for clinically indicated CT of the abdomen and/or pelvis to
evaluate for suspected intra-abdominal infection. Subjects will be randomized to receive
either weight-based low-osmolality iodinated contrast material or saline. The primary outcome
measure will be the incidence of stage II AKI by AKIN (Acute Kidney Injury Network) criteria.